298 related articles for article (PubMed ID: 32344150)
1. Epigenetic regulation of anterior segment diseases and potential therapeutics.
Chen E; Bohm K; Rosenblatt M; Kang K
Ocul Surf; 2020 Jul; 18(3):383-395. PubMed ID: 32344150
[TBL] [Abstract][Full Text] [Related]
2. Epigenetics and ocular diseases: from basic biology to clinical study.
Yan B; Yao J; Tao ZF; Jiang Q
J Cell Physiol; 2014 Jul; 229(7):825-33. PubMed ID: 24318407
[TBL] [Abstract][Full Text] [Related]
3. Gene Therapy in the Anterior Eye Segment.
Amador C; Shah R; Ghiam S; Kramerov AA; Ljubimov AV
Curr Gene Ther; 2022; 22(2):104-131. PubMed ID: 33902406
[TBL] [Abstract][Full Text] [Related]
4. Review: Epigenetic mechanisms in ocular disease.
He S; Li X; Chan N; Hinton DR
Mol Vis; 2013; 19():665-74. PubMed ID: 23559860
[TBL] [Abstract][Full Text] [Related]
5. Recent advances in topical nano drug-delivery systems for the anterior ocular segment.
Lakhani P; Patil A; Majumdar S
Ther Deliv; 2018 Feb; 9(2):137-153. PubMed ID: 29325511
[TBL] [Abstract][Full Text] [Related]
6. Recent Advances in Topical Ocular Drug Delivery.
Yellepeddi VK; Palakurthi S
J Ocul Pharmacol Ther; 2016 Mar; 32(2):67-82. PubMed ID: 26666398
[TBL] [Abstract][Full Text] [Related]
7. Ocular Disease Therapeutics: Design and Delivery of Drugs for Diseases of the Eye.
Cheng KJ; Hsieh CM; Nepali K; Liou JP
J Med Chem; 2020 Oct; 63(19):10533-10593. PubMed ID: 32482069
[TBL] [Abstract][Full Text] [Related]
8. Epigenetics in Eye Development and Ocular Disorders: A Brief Review.
Kuchay RAH; Hassan A; Mir YR
Curr Mol Med; 2023; 23(9):843-848. PubMed ID: 36200196
[TBL] [Abstract][Full Text] [Related]
9. State of the art clinical efficacy and safety evaluation of N-acetylcarnosine dipeptide ophthalmic prodrug. Principles for the delivery, self-bioactivation, molecular targets and interaction with a highly evolved histidyl-hydrazide structure in the treatment and therapeutic management of a group of sight-threatening eye diseases.
Babizhayev MA; Kasus-Jacobi A
Curr Clin Pharmacol; 2009 Jan; 4(1):4-37. PubMed ID: 19149498
[TBL] [Abstract][Full Text] [Related]
10. Biological macromolecules for ophthalmic drug delivery to treat ocular diseases.
Krishnaswami V; Kandasamy R; Alagarsamy S; Palanisamy R; Natesan S
Int J Biol Macromol; 2018 Apr; 110():7-16. PubMed ID: 29378276
[TBL] [Abstract][Full Text] [Related]
11. Anterior eye segment drug delivery systems: current treatments and future challenges.
Molokhia SA; Thomas SC; Garff KJ; Mandell KJ; Wirostko BM
J Ocul Pharmacol Ther; 2013 Mar; 29(2):92-105. PubMed ID: 23485091
[TBL] [Abstract][Full Text] [Related]
12. [The advances of epigenetic research in eye].
Li XH; He SK
Zhonghua Yan Ke Za Zhi; 2013 Jun; 49(6):568-73. PubMed ID: 24119972
[TBL] [Abstract][Full Text] [Related]
13. Review: Environmental impact on ocular surface disorders: Possible epigenetic mechanism modulation and potential biomarkers.
Busanello A; Santucci D; Bonini S; Micera A
Ocul Surf; 2017 Oct; 15(4):680-687. PubMed ID: 28572031
[TBL] [Abstract][Full Text] [Related]
14. Recent patents on ocular drug delivery systems.
Conway BR
Recent Pat Drug Deliv Formul; 2008; 2(1):1-8. PubMed ID: 19075892
[TBL] [Abstract][Full Text] [Related]
15. Cell penetrating peptides in ocular drug delivery: State of the art.
Pescina S; Ostacolo C; Gomez-Monterrey IM; Sala M; Bertamino A; Sonvico F; Padula C; Santi P; Bianchera A; Nicoli S
J Control Release; 2018 Aug; 284():84-102. PubMed ID: 29913221
[TBL] [Abstract][Full Text] [Related]
16. Dendrimer nanoparticles for ocular drug delivery.
Kambhampati SP; Kannan RM
J Ocul Pharmacol Ther; 2013 Mar; 29(2):151-65. PubMed ID: 23410062
[TBL] [Abstract][Full Text] [Related]
17. Anterior segment optical coherence tomography: its application in clinical practice and experimental models of disease.
Jiao H; Hill LJ; Downie LE; Chinnery HR
Clin Exp Optom; 2019 May; 102(3):208-217. PubMed ID: 30270476
[TBL] [Abstract][Full Text] [Related]
18. Advances in ocular drug delivery.
Rawas-Qalaji M; Williams CA
Curr Eye Res; 2012 May; 37(5):345-56. PubMed ID: 22510004
[TBL] [Abstract][Full Text] [Related]
19. Delivery of therapeutics for deep-seated ocular conditions - status quo.
Nguyen H; Eng S; Ngo T; Dass CR
J Pharm Pharmacol; 2018 Aug; 70(8):994-1001. PubMed ID: 29675844
[TBL] [Abstract][Full Text] [Related]
20. Episcleral, intrascleral, and suprachoroidal routes of ocular drug delivery - recent research advances and patents.
Gilger BC; Mandal A; Shah S; Mitra AK
Recent Pat Drug Deliv Formul; 2014; 8(2):81-91. PubMed ID: 25001638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
